FY2022 EPS Estimates for Aerovate Therapeutics, Inc. Decreased by Analyst (NASDAQ:AVTE)
FY2022 EPS Estimates for Aerovate Therapeutics, Inc. Decreased by Analyst (NASDAQ:AVTE)
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) – Wedbush cut their FY2022 EPS estimates for shares of Aerovate Therapeutics in a research report issued on Tuesday, November 15th. Wedbush analyst L. Moussatos now forecasts that the company will post earnings of ($2.06) per share for the year, down from their previous estimate of ($1.92). Wedbush currently has a "Outperform" rating and a $27.00 target price on the stock. The consensus estimate for Aerovate Therapeutics' current full-year earnings is ($1.94) per share. Wedbush also issued estimates for Aerovate Therapeutics' Q4 2022 earnings at ($0.56) EPS, Q1 2023 earnings at ($0.55) EPS, Q2 2023 earnings at ($0.55) EPS, Q3 2023 earnings at ($0.54) EPS, Q4 2023 earnings at ($0.54) EPS, FY2023 earnings at ($2.18) EPS, FY2024 earnings at ($2.11) EPS, FY2025 earnings at ($2.35) EPS and FY2026 earnings at ($1.10) EPS.
Aerovate治疗公司(纳斯达克:AVTE-GET评级)--韦德布什在11月15日星期二发布的一份研究报告中下调了他们对Aerovate治疗公司股票2022财年每股收益的估计。韦德布什分析师L·穆萨托斯现在预测,该公司今年的每股收益将为2.06美元,低于此前预测的1.92美元。韦德布什目前对该股的评级为“跑赢大盘”,目标价为27美元。对Aerovate治疗公司目前全年收益的普遍估计为每股1.94美元。韦德布什还发布了对Aerovate治疗公司2022年第四季度每股收益(0.56美元)、2023年第一季度每股收益(0.55美元)、2023年第二季度每股收益(0.55美元)、2023年第三季度每股收益(0.54美元)、2023年第四季度每股收益(0.54美元)、2023财年每股收益(2.18美元)、2024财年每股收益(2.11美元)、2025财年每股收益(2.35美元)和2026财年每股收益(1.10美元)的估计。
Separately, BTIG Research downgraded shares of Aerovate Therapeutics from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 16th.
另外,BTIG Research在8月16日星期二的一份研究报告中将Aerovate治疗公司的股票评级从“买入”下调至“中性”。
Aerovate Therapeutics Trading Down 2.4 %
Aerovate治疗公司股价下跌2.4%
Aerovate Therapeutics (NASDAQ:AVTE – Get Rating) last issued its quarterly earnings data on Monday, August 15th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.03).
Aerovate治疗公司(纳斯达克:AVTE-GET评级)最近一次发布季度收益数据是在8月15日(星期一)。该公司公布了本季度每股收益(0.49美元),低于普遍预期的(0.46美元)和(0.03美元)。
Insider Activity
内幕活动
In other news, insider Ralph Niven sold 2,250 shares of Aerovate Therapeutics stock in a transaction on Wednesday, October 5th. The shares were sold at an average price of $15.75, for a total value of $35,437.50. Following the transaction, the insider now directly owns 1,609 shares of the company's stock, valued at approximately $25,341.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Aerovate Therapeutics news, insider Benjamin T. Dake sold 6,198 shares of the business's stock in a transaction on Friday, November 11th. The shares were sold at an average price of $20.69, for a total value of $128,236.62. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Ralph Niven sold 2,250 shares of the business's stock in a transaction on Wednesday, October 5th. The shares were sold at an average price of $15.75, for a total transaction of $35,437.50. Following the completion of the transaction, the insider now directly owns 1,609 shares in the company, valued at $25,341.75. The disclosure for this sale can be found here. Insiders have sold 58,564 shares of company stock valued at $1,052,353 in the last ninety days. 17.80% of the stock is currently owned by company insiders.
其他消息方面,内部人士拉尔夫·尼文在10月5日星期三的一笔交易中出售了2,250股Aerovate治疗公司的股票。这些股票的平均价格为15.75美元,总价值为35,437.50美元。交易完成后,这位内部人士现在直接持有该公司1,609股股票,价值约25,341.75美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接。在Aerovate治疗公司的其他消息中,内部人士Benjamin T.Dake在11月11日星期五的一笔交易中出售了6198股该公司的股票。这些股票的平均价格为20.69美元,总价值为128,236.62美元。这笔交易是在提交给美国证券交易委员会的法律文件中披露的,该文件可通过这个环节。此外,内部人士拉尔夫·尼文在10月5日星期三的一次交易中出售了2250股该公司的股票。这些股票以15.75美元的平均价格出售,总成交金额为35,437.50美元。交易完成后,这位内部人士现在直接持有该公司1,609股股票,价值25,341.75美元。关于这次销售的披露可以找到这里。在过去的90天里,内部人士已经出售了58,564股公司股票,价值1,052,353美元。公司内部人士目前持有该公司17.80%的股份。
Hedge Funds Weigh In On Aerovate Therapeutics
对冲基金对Aerovate Treeutics的看法
Institutional investors have recently bought and sold shares of the company. UBS Group AG acquired a new position in Aerovate Therapeutics in the 3rd quarter valued at $26,000. Amalgamated Bank purchased a new stake in shares of Aerovate Therapeutics during the 1st quarter worth $27,000. Parkwood LLC purchased a new stake in shares of Aerovate Therapeutics during the 2nd quarter worth $32,000. Russell Investments Group Ltd. purchased a new stake in shares of Aerovate Therapeutics during the 2nd quarter worth $32,000. Finally, Tower Research Capital LLC TRC boosted its position in shares of Aerovate Therapeutics by 569.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,449 shares of the company's stock worth $57,000 after purchasing an additional 2,934 shares in the last quarter.
机构投资者最近买卖了该公司的股票。瑞银集团在第三季度收购了Aerovate治疗公司的一个新头寸,价值2.6万美元。合并银行在第一季度购买了Aerovate治疗公司价值2.7万美元的新股份。Parkwood LLC在第二季度购买了Aerovate治疗公司价值3.2万美元的新股份。罗素投资集团有限公司在第二季度购买了价值3.2万美元的Aerovate治疗公司的新股份。最后,Tower Research Capital LLC TRC在第三季度将其在Aerovate Treeutics的股票头寸增加了569.7%。Tower Research Capital LLC TRC现在拥有3449股该公司股票,价值5.7万美元,上个季度又购买了2934股。
Aerovate Therapeutics Company Profile
Aerovate治疗公司简介
(Get Rating)
(获取评级)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Aerovate治疗公司是一家临床阶段的生物制药公司,专注于开发能够改善美国罕见心肺疾病患者生活的药物。该公司专注于推进AV-101,这是一种治疗肺动脉高压的伊马替尼干粉吸入剂,目前处于2b期/3期试验。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Aerovate Therapeutics (AVTE)
- Does ASML's November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
- Is Advance Auto Parts a Buy After its Earnings Crash?
- BJ's Wholesale Club: Beware The Sell-Side
- The Next Catalyst For Mullen Automotive Stock Is December 23rd
- 免费获取StockNews.com关于Aerovate治疗(AVTE)的研究报告
- ASML的11月拉力赛有后劲吗?
- Verra移动库存已返回空间站
- 在盈利暴跌后,Advance Auto Parts是一笔买入吗?
- BJ‘s批发俱乐部:当心卖方
- 马伦汽车股票的下一个催化剂是12月23日
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Aerovate治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Aerovate治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。